Venom immunotherapy induces monocyte activation

Clinical and Experimental Allergy

Volumn 31, Issue 8, 2001, Pages 1303-1309

  Magnan, A ^a,c   Marin, V ^b   Mely L ^a   Birnbaum, J ^a   Romanet, S ^a   Bongrand, P ^b   Vervloet, D ^a  

^a Centre d'Investigation Clinique   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c Service de Pneumo Allergologie   (France)

Author keywords

Allergy; Hymenoptera venom; IL 10; IL 12; Immunotherapy; Monocyte; Th1; Th2; TNF

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; VENOM;

ADULT; AGED; ARTICLE; BLOOD CULTURE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INSECT STING; MALE; MONOCYTE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; T LYMPHOCYTE; TH2 CELL; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; BEE VENOMS; CELLS, CULTURED; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYMENOPTERA; INTERLEUKIN-10; INTERLEUKIN-12; MACROPHAGE ACTIVATION; MALE; MIDDLE AGED; MONOCYTES; TUMOR NECROSIS FACTOR-ALPHA; WASP VENOMS;

EID: 0035724637     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01171.x     Document Type: Article

References (29)

1. Allergen immunotherapy: Therapeutic vaccines for alleric diseases. A WHO position paper
2. Immunologic changes associated with allergen immunotherapy
3. Mechanisms of allergen-specific immunotherapy
4. Role of interleukin-10 in specific immunotherapy
5. Revisiting the Th1/Th2 paradigm
6. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro
7. Allergen immunotherapy decreases interleukin-4 production in CD4+ T cells from allergic individuals
8. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures
9. Bee venom immunotherapy induces a shift in cytokine responses from a Th2 to a Th1 dominant pattern. Comparison of rush and conventional immunotherapy
10. Venom immunotherapy modulates interleukin-4 and interferon-γ messenger RNA expression of peripheral T lymphocytes
11. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late phase cutaneous responses
12. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ
13. Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-γ production in CD4+ T cells
14. Decreased release of histamine and sulfidoleucotrienes by human peripheral blood leucocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-γ production of T cells
15. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type
16. Interleukin-12 as a target for modulation of the inflammatory response in asthma
17. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF) -alpha: Induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses
18. Rapid hymenoptera venom immunotherapy. Comparative safety of three protocols
19. Non specific binding by macrophages. Existence of different adhesive mechanisms and modulation by metabolic inhibitor
20. IL-12-deficient mice are defective in IFN-γ production and type I cytokine responses
21. Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice
22. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy
23. Regulation of interleukin-12 expression in human monocytes: Selective priming by interferon-γ of lipopolysaccharide-inducible p35 and p40 genes
24. IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and -independent mechanisms
25. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-α and IL-12 production by monocytes and dentritic cells
26. Tumor necrosis factor-alpha and interleukin-6 production by mononuclear phagocytes from allergic asthmatics after IgE-dependent stimulation
27. Tumour necrosis factor-alpha in tears of atopic patients after conjunctival challenge
28. Interleukin-10: An anti-inflammatory cytokine with therapeutic potential
29. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface maker expression in venom-allergic subjects